spacer
home > pmps > spring 2018 > protective packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Protective Packaging

Pharmaceutical companies and their logistics partners are enjoying more availability and scope of temperature-controlled distribution lanes within pharma supply chains than ever before. This means more choice when specifying thermal protection solutions that are both cost-effective and fit for purpose.

This has led to the current trend of moving away from temperature-controlled packaging, particularly as well-controlled distribution lanes and effective thermal covers become the norm. Designed to provide a greater level of protection within uncontrolled distribution lanes and general cargo facilities, temperature-controlled packaging can be costly and offer low payload efficiency, particularly for controlled distribution lanes where they are often over-engineered and provide a higher level of protection than actually required.

As a result, thermal protection solutions are becoming increasingly popular. However, this is bringing its own set of challenges, including a lack of a consistent approach to product performance assessment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin Valentine is Chief Technology Officer at TP3 Global and Cool Logistics India. He has been working in the temperature-controlled packaging industry for over 26 years. Following a 10 year career at Laminar Medica, Kevin founded Cool Logistics in 2000. He joined Cool Logistics India and TP3 Global in 2016, where he has led the development of a new technical centre to provide enhanced technical services to customers. Kevin has also overseen the creation of several new products for improved thermal protection of pharmaceutical products and other temperature-sensitive cargo.
spacer
Kevin Valentine
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

Pre-Filled Syringes & Injectable Drug Devices Europe

16-17 January 2019, Copthorne Tara Hotel, London

SMi is proud to present their 11th annual European conference and exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019, in London.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement